Virbac Strengthens Feline Portfolio With Acquisition Of Thyronorm® For Feline Hyperthyroidism

2 weeks ago
270 views

Posted
15th January, 2026 12h29

Author
Virbac Animal Health

Virbac is pleased to announce the acquisition of Thyronorm®, the market-leading¹ treatment for feline hyperthyroidism, from Norbrook. This strategic move reinforces Virbac’s commitment to improving the quality of life for senior cats and supporting veterinary practices with advanced solutions for chronic conditions.

Hyperthyrodism is believed to be the most common hormonal disease in cats worldwide. In the UK, it is thought to affect over 10% of cats² and can lead to severe metabolic imbalances, including weight loss, irritability, tachycardia, and gastrointestinal issues. If left untreated, the condition can be fatal. With the growing population of household cats and their longer lifespans, effective and practical treatments are more important than ever.

Marketed since 2016, Thyronorm® is an award-winning liquid formulation containing thiamazole, that simplifies administration compared to tablets and enables precise dosing for both veterinary surgeons and pet owners. This innovation represents a tangible improvement in managing feline hyperthyroidism and enhancing daily care for senior cats.

During the product handover veterinary practices can continue to purchase Thyronorm® from their usual wholesaler, and all practice support activities and retrospective commercial rebates remain unchanged. Norbrook and Virbac are working closely together to ensure all practice support activities are smoothly handed over from Norbrook Account Managers to Virbac Territory Managers.

“Virbac’s global presence and strong veterinary relationships position us to expand access and education around Thyronorm® said Vicky Le Fanu, Product Manager at Virbac. ‘We are delighted to add such a well-respected product to our growing feline and endocrinology portfolios”.

“This acquisition reflects our commitment to advancing animal health by investing in innovative specialty products for conditions with growing unmet needs. Virbac has a proven track record of integrating and growing such assets, and we look forward to working closely with Norbrook to support even more senior cats with this condition “, added Paul Martingell, CEO of Virbac Group.

For more information contact your Virbac Territory Manger or Virbac directly Tel:01359 243243 Email: [email protected]

^References:

1. ^{Kynetec VetTrak Sales Data, October 2025}
2. ^{Wakeling J, Melian C, Font A, et al. Evidence for differing incidences of feline hyperthyroidism in London UK and Spain. In: Congress Proceedings 15th ECVIM-CA, Glasgow, Scotland, Poster 43; 2005, p 220}

More from Virbac Animal Health

• Virbac announces the arrival of Canixin® L, a new L2 Leptospirosis vaccine for dogs
• Virbac Announces Complimentary CPD Webinar: Introducing Vikaly™ – A New Era in Feline CKD Management
• Virbac Launches Vikaly™: The World’s First 2-in-1 Medicated Food for Cats
• Virbac Champions Excellence at the 2025 Cream Awards in the Dairy Vet Categories
• VMD grants marketing authorisation for Syvazul® BTV3 in Great Britain